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HISTORICAL OVERVIEW
Thalassemia was first described by two American pedia-
tricians, Thomas B. Cooley and Pearl Lee [1]. They re-
ported a series of five children with severe anemia, growth
retardation, and peculiar bone abnormalities [2-3]. It was
first called “erythroblastic anemia.” The term thalasse-
mia was later coined by George Whipple [4]. Thalassemia
roughly translates to “anemia of the sea,” signifying the
fact that most patients were of Mediterranean origin.
Insight into the pathophysiology came when Sir David
Weatherall and Dr. John Clegg and their colleagues were
able to isolate and separate the thalassemiaglobin chain.
They deduced that the culprit was an imbalance in chain
synthesis [5]. Their theory still holds till now. Beta-
thalassemia is a defect in the synthesis of the beta chain 
of the hemoglobin leading to imbalance in the α/β ratio 
in the red blood cells (RBC), ineffective erythropoiesis, 
and a spectrum of anemia [6]. Thalassemia major (TM) is
when the synthesis defect is profound leading to severe
anemia requiring blood transfusion within the first year of
life. On the other hand of the spectrum, we have thalas-
semia minor (Tm) which is completely asymptomatic and
only manifests as a mild hypochromic, microcytic ane-
mia. Sturgeon described a third group of patients with
manifestations that are too severe to be called minor and
too mild to be called major. He suggested the term tha-
lassemia intermedia for this population [7].
GENETICALLY SPEAKING
Thalassemia intermedia (TI) is in itself a spectrum of 
diseases. Mildly affected patients remain completely
asymptomatic till adult life, with their only abnormality
being mild anemia with hemoglobin (Hb) levels main-
tained between 7-10 g/dl. More severely affected patients
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ABSTRACT : Thalassemia intermedia is a genetical-
ly diverse group of diseases that is the result of an
imbalance in the production of the alpha and beta
chains with ensuing chronic hemolysis, ineffective ery-
thropoiesis, and iron overload. Resulting complications
include bone changes, hypercoagulability, and end-
organ damage due to iron overload. This decade has
witnessed major breakthroughs in the management of
thalassemia. In this article, we examine these novelties
in therapy including iron chelation therapy, stem cell
transplant, and gene therapy. Iron chelation therapy
has been revolutionized with the advent of deferasirox,
a once-daily oral iron chelator, that has been shown to
be safe and efficacious. Gene therapy was also at the
core of this revolution with the discovery of novel gene
elements and viral vectors allowing for better control
and improved outcomes.
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RÉSUMÉ : La thalassémie intermédiaire englobe un
groupe de maladies diverses résultant d’un déséquilibre
entre la production des chaînes alfa et bêta qui aboutit
à  une hémolyse chronique, une érythropoïèse inefficace
et une surcharge en fer. Les complications engendrées
par cette maladie sont un changement dans la constitu-
tion des os, un état d’hypercoagulabilité, et des organes
majeurs endommagés suite au surplus de fer. La der-
nière décennie a vu d’importantes avancées dans le
traitment de la thalassémie. Sont examinées ici les
toutes dernières thérapeutiques : la chélation du fer, 
la greffe de cellules souches et la thérapie génétique.
L’introduction de deferasirox, un chélateur du fer
administré une fois par jour par voie orale, a révolu-
tionné la chélation du fer et s’est imposé comme étant
un médicament sûr et efficace. La thérapie génétique a
aussi été une innovation charnière dans les nouveaux
traitements, surtout avec la découverte récente d’élé-
ments génétiques et vecteurs viraux qui permettent un
meilleur contrôle et améliorent les résultats.
Mots-clés: thalassémie, thalassémie intermédiaire, chéla-
tion du fer, érythropoïèse inefficace, greffe de cellules souches,
surcharge en fer, hémoglobinopathie, thérapie génétique, inhi-
biteur de Jak2
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present younger, between 2 and 6 years of age, and require
transfusions for normal and sustained growth [8]. While
Tm is the result of disruption of one of the beta chains and
TM is the result of disruption of both of these chains, TI
has a myriad of genotypes associated with it and is still a
clinical diagnosis. It usually results from a homozygous or
a compound heterozygous mutation [9]. Rarely, it can also
result from only one chain being affected, making it dom-
inantly inherited [10]. TI is milder than TM because of
several reasons. It can be due to inheritance of a mild
mutation, resulting in subnormal synthesis of beta chains
instead of complete absence. It can also be due to coinher-
itance of determinants that increase gamma-chain produc-
tion to stabilize the excess alpha chains. Coinheritance of
alpha-thalassemia will also lead to a TI phenotype since
less alpha chains will remain unpaired. One can inherit
triplicated or quadruplicated alpha genotype associated
with beta heterozygosity and manifest a TI phenotype.
Polymorphisms that alter bone, iron, and bilirubin metab-
olism can also affect the clinical expression of the disease.
These are called tertiary modifiers. Environmental and
socioeconomic factors also play a role in the presentation.
With so many factors in play (Table I), it is no surprise that
TI has such a wide range of clinical presentations.
Some studies have aimed at stratifying TI patients by
severity, and attempted to predict a genotype-phenotype
relationship to better tailor the treatment guidelines [11-
12]. Phadke and Agarwal devised a score based on the clin-
ical presentation to classify patients. The score was com-
posed of relevant clinical characteristics such as age at pre-
sentation, severity of the anemia, extent of growth retarda-
tion and bone marrow hyperplasia, blood transfusion
requirements, and need for splenectomy [13]. This score
might prove to be of great value in classifying patients and
relating genotype to phenotype when developing treatment
guidelines; however, more studies will have the final say in
this. The diagnosis of TI remains a clinical one and can be
very challenging at both ends of the spectrum.
PATHOPHYSIOLOGY
The alpha and beta chains in a normal red blood cell
(RBC) should precisely match each other. In beta-thalas-
semia, underproduction of the beta chains causes excess,
unstable alpha chains to deposit in the RBC, thus produc-
ing oxidative damage to the membrane and subsequent
lysis of the cells – this is ineffective erythropoiesis [14].
This causes the bone marrow to hypertrophy, resulting in
characteristic deformities of the skull and face. Cortical
thinning and pathological fractures are also common [15].
The primary determinant of the anemia is the degree of
ineffective erythropoiesis rather than the degree of hemo-
lysis, which only plays a secondary role [16]. Instead,
hemolysis is linked to the hypercoagulable state in TI [17]
leading to silent infarcts [18] and pulmonary hyperten-
sion. The anemia and the ineffective erythropoiesis in-
crease intestinal iron absorption leading to iron overload,
which causes heart failure, endocrine abnormalities and
others (Figure 1).
COMPLICATIONS
The combination of ineffective erythropoiesis, chronic
hemolysis and iron overload eventually culminate in the
complications we see in TI. Our first attempt at under-
standing the complications of TI came from comparing TI
and TM patients from two centers in Lebanon and Italy.
The results were remarkable in that some complications
were exclusively found in TI patients [16]. A better under-
standing of the complications came from the OPTIMAL
CARE study. This study was a cross-sectional survey of
584 TI patients from six centers throughout the Middle
East and Italy. Different complications were correlated
with different exposures and treatments [19]. The compli-
cations are discussed below and summarized in Table II.
A. Thrombophilia
TI patients are at a higher risk of thrombosis than TM
patients. Out of 2,190 TI patients, 3.9% experienced a
thrombotic event compared to only 0.9% of 6,670 TM
patients [20]. The events were mainly venous. Splenecto-
mized patients were at a higher risk of thrombosis than
non-splenectomized patients. Additional risk factors for
thrombosis were low hemoglobin concentration (< 9 g/dl)
and transfusion-independence. Studies are still lacking on
this subject but there are several proposed mechanisms.
RBC remnants express negatively charged phosphati-
dylserine residues on their membranes which act as pro-
coagulants, initiating thrombosis [21-22]. Activation of
platelets, endothelial cells, monocytes, and depletion of
TABLE I
MODIFIERS OF THALASSEMIA INTERMEDIA
Mutation affecting the beta globin is mild Resulting imbalance between alpha and beta chains is mild
Co-inheritance of alpha and beta thalassemia Imbalance is compensated for by less of the other chain being synthesized
Inheritance of modifiers that increase gamma chain Excess alpha chains will pair with excess gamma chains decreasing the deleterious  
production effect of the free alpha chains
Tertiary modifiers Genes not related to globin synthesis but that may play a role in the presentation
(iron absorption, bilirubin metabolism, bone metabolism, cardiovascular disease, and 
susceptibility to Infection)
Environmental and socioeconomic factors
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anti-thrombotic factors are also incriminated along with
the cardiac, endocrine, and hepatic dysfunction [23].
Other risk factors include age [24], previous thrombo-
embolic events, and family history.
These patients are important to identify and treat be-
cause sequelae include pulmonary hypertension with en-
suing secondary heart failure [25] and silent brain abnor-
malities [18, 26]. Recommended therapies include aspirin
or other platelet anti-aggregants in the case of thrombo-
cytosis, or anticoagulant agents such as low molecular
weight heparin in patients with documented thrombosis 
or for those undergoing surgery. Blood transfusions might
be considered as they dilute the circulating damaged
RBCs. More studies are needed to establish a risk-assess-
ment model that would stratify the patients according to
their risks and guide a tailored therapy to this issue.
B. Iron overload 
Iron is controlled by a negative feedback loop. Inflam-
mation and excess plasma iron is a stimulant for the tran-
scription of hepcidin. Hepcidin interacts with ferroportin 
– the iron exporter – on the basolateral surfaces of hepa-
tocytes and the intestinal epithelium and causes its inter-
nalization and degradation [27]. This traps iron inside the
cells and makes it less available in the blood stream. In the
hepatocytes, macrophages, and other cells of the reticulo-
endothelial system, it is stored in its ferritin-bound form
for later use. In the endothelial cells, intracellular iron is
shed with the shedding of the epithelium. Hypoxia, ane-
mia, and a demand for erythropoiesis suppress hepcidin,
making more iron available for the bone marrow through
increased intestinal absorption and better recycling of 
catabolic iron from the reticuloendothelial system [28].
Ineffective erythropoiesis increases expression of growth
differentiation factor 15 (GDF15) and hypoxia-inducible
transcription factors (HIFs) [28] which cause down-regu-
lation of hepcidin. This increases intestinal iron absorp-
tion and depletes the macrophages of their iron stores.
FIGURE 1
Pathophysiology of thalassemia intermedia in a nutshell.
An imbalance in the ratio of alpha to non-alpha (beta) chains
leads to cell lysis and ineffective erythropoiesis. This leads to
characteristic bony changes, hypercoagulability, and increased
gastrointestinal iron absorption. Osteoporosis and fractures,
silent brain infarcts, pulmonary hypertension, and iron overload
ensue.
TABLE II
COMPLICATIONS OF THALASSEMIA INTERMEDIA
AND THEIR MANAGEMENT
Complications Management
Hypercoagulability Acetyl salicylic acid or other
anti-platelet aggregant for
thrombocytosis
LMWH for previous thrombosis
Iron overload Iron chelation therapy and regular
assessment of iron loading
Splenomegaly & hypersplenism Splenectomy, with careful
consideration of the increased
adverse events
Cholelithiasis Cholecystectomy
Extramedullary hematopoiesis Radiotherapy, hydroxyurea, or
transfusion therapy
Pulmonary hypertension Hydroxyurea
Sildenafil still under study
Leg ulcers Hypertransfusion and elevation of
the lower extremities
Zinc supplementation, pentoxifylline,
and hydroxyurea ± erythropoietin
Endocrine dysfunction Iron chelation therapy and regular
follow-up
Hepatitis Using effective transfusion regimens
Careful monitoring for hepatocellular
carcinoma
LMWH: low molecular weight heparin
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After all the iron saturates the transferrin stores, it is trans-
ported as the toxic non-transferrin-bound-iron. The end
result is its deposition in the parenchyma of the liver,
heart, endocrine organs, and others.
Body iron levels are usually assessed by ferritin values.
However, studies have shown that ferritin underestimates
the total iron burden in TI [29]. For the same value of liver
iron concentration, ferritin values in TI patients were sig-
nificantly lower than TM patients. A proposed mechanism
for this is that iron in transfused patients is preferentially
distributed to the reticuloendothelial system, thus ferritin
is more readily synthesized and exported [28]. This is 
in contrast to transfusion-independent TI patients, where
low hepcidin depletes the reticuloendothelial system of its
iron stores, thus ferritin will be low. Other methods of
evaluating body iron stores include determination of liver
iron concentration by biopsy or more recently by non-
invasive techniques such as R2 MRI.
C. Splenectomy and cholecystectomy
The main indications for splenectomy in TI are poor
growth and development, increased transfusion demand,
hypersplenism, and splenomegaly [30]. However, splen-
ectomy appears to contribute to an increased risk of
thrombosis [22, 31]. Splenectomy is now less common
than before and is performed later in life [8]. Gallstones
are common in TI because of the ineffective erythro-
poiesis and peripheral hemolysis. That is why the gall-
bladder should be inspected during splenectomy to avoid
further complications.
D. Extramedullary hematopoiesis
Extramedullary hematopoiesis (EMH) is when erythro-
poietic tissue outside marrow spaces in bones increases to
compensate for the chronic state of anemia that accompa-
nies TI. This will lead to the formation of erythropoietic
masses that primarily affect the spleen, liver, and lymph
nodes [8]. These masses can cause local symptoms such
as neurological symptoms and spinal cord compressions
[32-33]. Splenic enlargement can cause symptoms such as
early satiety, left upper quadrant pain, and even raises con-
cerns about splenic rupture [30]. Extramedullary hemato-
poiesis is routinely managed by radiotherapy, hydroxy-
urea, or transfusion therapy [32, 34-35].
E. Pulmonary hypertension
Pulmonary hypertension (PH) is defined as pulmonary
artery pressure of > 25 mmHg at rest or > 30 mmHg dur-
ing exercise [36]. In TI, the prevalence is estimated to be
around 59%.This, in turn, contributes to an increased inci-
dence of congestive heart failure [37]. The etiology of PH
in TI is multifactorial. PH results from interplay of vaso-
constriction, vascular smooth muscle proliferation, and
dysfunctional endothelium with resulting thrombosis, all
of which contribute to luminal narrowing and right-sided
failure. Major risk factors include advancing age and a
history of splenectomy [38]. Autopsy studies in thalas-
semia patients have revealed common histopathological
findings that include plexiform and concentric medial
hyperplastic pulmonary vascular lesions, and in situ pul-
monary artery thrombosis [39-40]. The factors that culmi-
nate in these pathologies are most likely the result of the
long-term sequelae of splenectomy, red cell membrane
pathology, coagulation abnormalities, excess arginase
activity, low nitric oxide bioavailability, platelet activa-
tion, oxidative stress, iron overload, and chronic hemoly-
sis [41-45]. The correlation of ferritin with PH is still con-
troversial with one study indicating no correlation [46]
while another study reporting a strong correlation between
an elevated tricuspid regurgitant jet velocity (TRV) and
serum ferritin [47]. Hemolysis disables the arginine-nitric
oxide pathway by releasing erythrocyte arginase [48] and
cell-free hemoglobin [43]. With the consumption of nitric
oxide and arginine, endothelial dysfunction ensues, and
along with the intravascular hemolysis, this will create a
procoagulant state [49]. Iron overload, and the subsequent
oxidative stress, can also contribute to increasing the pul-
monary vasculature resistance through various mecha-
nisms. They induce pulmonary fibrosis and affect the
pump itself through cardiac siderosis [50]. The hypoxe-
mia, along with the chronic anemia, will also exacerbate
the vasoconstriction [38].
Currently, there are no guidelines for the treatment of
PH in TI specifically. In one small trial, PH was absent in
patients taking hydroxyurea, suggesting a protective role,
but further studies are needed [51]. Two small studies
reported improvement in exercise tolerance in response to
sildenafil [52-53]. General recommendations for the man-
agement of PH now are adequate treatment of thalasse-
mia, any precipitating factors or associated diseases, in
addition to supportive measures [38]. A multidisciplina-
ry approach is needed and a cardiopulmonary specialist
should be on board.
F. Leg ulcers, endocrine dysfunction, and hepatitis
TI patients are also at risk for other complications. Leg
ulcers occur more commonly in older patients. Leg ulcers
develop in some patients with low hemoglobin and do not
develop in others, even though they are maintained at 
the same amount of fetal hemoglobin, implying that it is
multifactorial in origin. The skin might be at a lower oxy-
gen tension due to the anemia, making it fragile and more
prone to break with minimal trauma. These also cause
impaired healing. These are usually managed by an
intense transfusion regimen to elevate the hemoglobin
concentration by a minimum of 2 g/dl. Other possible
interventions include elevating the end of the bed so as to
keep the lower limbs at a level above the heart. This pro-
vides better venous return and increases the perfusion
pressure of the affected area [8]. Zinc supplementation
[54], pentoxifylline, and hydroxyurea, with or without
erythropoietin [55] are also possible options.
While endocrine dysfunction can be quite common 
in TM, it is quite rare in TI. Patients generally experi-
ence late puberty, but their sexual development is normal
and their fertility preserved. However, hypothyroidism
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can be a late occurrence sometimes [8].
Viral hepatitis is much rarer in TI than in TM due to the
fact that TI patients are less often transfused. Neverthe-
less, the risk is not absent and careful monitoring should be
undertaken [56]. New complications, such as hepatocellu-
lar carcinoma are emerging as patients are living longer.
MANAGEMENT
A. Iron chelation therapy ± transfusion therapy
The management of TI has come a long way this decade
with the new oral chelators, gene therapy, and Jak2 inhib-
itors [Table III]. Transfusion is the only available salvage
therapy when severe symptoms of anemia set in, including
developmental delay in the pediatric age group. Associated
risks include alloimmunisation, which is relatively com-
mon in TI, especially if transfusions are instituted after the
age of 12 months [57]. Rhesus and Kell phenotyping is
recommended prior to transfusion [58], with some physi-
cians advocating a short course of steroids for 3-5 days
concomitantly, even though this remains controversial.
The rate of iron loading in TI is variable and changes
with transfusional load. Iron loading in non-transfused
patients is estimated to be 2-5 grams per year [59] com-
pared to 7.5-15.1 grams per year for transfused patients
[60]. Iron loading should always be assessed by liver 
iron concentration (LIC), preferably by non-invasive MRI
imaging, and iron chelation therapy initiated accordingly.
Previously, an LIC of 7 mgFe/g dry weight was used to
initiate therapy; however, a recent study has found that an
LIC of 7 mgFe/g dry weight is associated with vascular
complications and an LIC of 6 mgFe/g dry weight is asso-
ciated with endocrine comorbidities, meaning that com-
plications would have already set in, and chelation should
start before that [61].
The gold standard remains desferrioxamine injections
which is given subcutaneously or intravenously for pro-
longed periods of time and is associated with significant
patient discomfort, decreased quality of life, and non-
compliance [62-63] despite significant mortality and mor-
bidity reductions [64]. Deferasirox, a once-daily oral iron
chelator, has been found to be safe and efficacious in
reducing iron burden in TI [65].
A novel oral iron chelator is also under development
for clinical use. The molecule is still in phase II clinical
trials, but the results seems promising [66]. Extensive
preclinical toxicological studies demonstrated a higher
no-observable-adverse-effect level (NOAEL) compared
to deferasirox.
B. Stem cell transplantation
Hematopoietic stem-cell transplantation is essentially
curative in properly selected candidates. Good candidates
with high success rates include pediatric patients who
have not developed complications such as viral hepatitis
or severe iron overload and who receive HLA-identical
related donor stem-cell transplants. The event-free sur-
vival for beta-thalassemia patients reported from several
groups is 80-90% with less than 10% mortality and mini-
mal morbidity, apart from impaired fertility [67-70]. The
problem is in the availability of donors. Disease-free sur-
vival is lower, and morbidity and mortality are higher with
unrelated haploidentical donors [71-73]. Definitive hema-
topoietic stem cells can be obtained from cord blood.
Several studies have assessed the use of cord-blood trans-
plantation for patients with thalassemia [69], and the out-
comes of related cord-blood stem cell transplantation for
beta-thalassemia are approaching those of conventional
bone marrow transplantation with disease-free survival 
of 90%. A cord-blood bank will also allow unrelated
transplants to take place, but data is still scarce [74-76].
The physician, patient, and everybody concerned
should be involved in the transplantation decision given
the associated morbidity, mortality, and cost of the proce-
dure (Figure 2).
TABLE III
MANAGEMENT OF THALASSEMIA INTERMEDIA
THERAPY
Conventional Non-conventional Radical
Transfusion therapy Gene therapy Stem cell transplant
Iron chelation therapy Fetal Hb modulation
Splenectomy
Supportive therapy
Psychological support
Hb: hemoglobin
FIGURE 2.  Stem cell transplant
After administering granulocyte-colony stimulating factor for
mobilizing stem cells, peripheral blood mononuclear cells are
harvested from peripheral blood. They are then purified and
selected for CD34+ cells. These cells are then cultured with viral
vectors carrying the normal beta-globin gene. The modified
stem cells are then engrafted in the patient after non-ablative
myelosuppression.
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C. Gene therapy
Thalassemia is an ideal disease for gene therapy since 
its genetic defect only affects the erythroid lineage in 
the hematopoietic system. The concept is simple, albeit
the mechanism is technically demanding. Hematopoietic
stem cells are harvested from the patient and infected with
a virus carrying the beta-globin gene along with its up-
stream regulatory elements, and then infused back after
myelosuppression. The fact that the patient’s own cells are
used overcomes the problem of scarcity of donors and
associated immunological complications.
A lot of work has been put to develop viral constructs
that are able to accommodate all the sequences needed
for the expression of the beta-globin gene. “Boundary
elements” are now frequently included in the genetic
complexes to include proper insertion. Boundary ele-
ments are sequences that flank the gene and delimit the
activity of the regulatory elements of that gene [77].
Another setback was the associated risk of leukemia with
the use of retroviral vectors. Therefore, lentiviral vectors
were developed and they have proven successful in
mouse models both in TM and TI [78-83]. A clinical trial
to test this lentiviral vector has already begun in 2007 on
two patients [84-85]. One of the patients needed rescue
with non-manipulated cells while the other achieved 10%
engraftment and was able to become transfusion inde-
pendent. The future of gene therapy probably lies in
induced pluripotent stem cells, which are human somatic
cells that are reprogrammed to form multipotent stem
cells [86-87].
D. Jak2 inhibitors
Data showed that in ineffective erythropoiesis, there is 
an accumulation of proliferating erythroid progenitors,
and an increase in the percentage of erythroid cells in the
S-phase. The thalassemia cells were associated with the
expression of certain cell-cycle regulatory genes such as
EpoR, Jak2, cyclin-A, Cdk2, Ki-67 and the antiapoptotic
protein Bcl-XL, and differentiated less. In thalassemic
mice, a Jak2 inhibitor reversed ineffective erythropoiesis
and decreased spleen size with limited effect on anemia.
Jak2 inhibitors would be expected to limit or reduce
splenomegaly, thus improving anemia and delaying the
need for splenectomy. A decrease in ineffective erythro-
poiesis is also expected to upregulate hepcidin, thus im-
proving the metabolism of total body iron content and
decreasing end-organ damage [88-90]. 
CONCLUSION
Despite all the advances in premarital screening and
genetic counseling, thalassemia remains an important
genetic disease. With migratory patterns and intermixing
of populations, thalassemia is no longer limited to its
places of origin. This decade has witnessed breakthroughs
in the treatment of thalassemia and we are now able to
provide better medical care that is making thalassemia
more of a chronic disease than a fatal one.
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